Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells

被引:80
作者
Blagosklonny, MV
Giannakakou, P
Wojtowicz, M
Romanova, LY
Ain, KB
Bates, SE
Fojo, T
机构
[1] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Genet Lab, NIH, Bethesda, MD 20892 USA
[3] Univ Kentucky, Med Ctr, Thyroid Canc Res Lab, Vet Adm Med Ctr, Lexington, KY 40536 USA
关键词
D O I
10.1210/jc.83.7.2516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the p53 status and the ability of exogenous wildtype (wt) p53 to affect chemosensitivity in three anaplastic thyroid carcinoma cell lines (BHT-101, SW-1736, and KAT-4). All three cell lines had nonfunctional p53. Treatment with mitomycin C or adriamycin did not result in accumulation of p53 or induction of p21(WAF1/CIP1) or Mdm-2 and did not cause Rb dephosphorylation. BHT-101 and KAT-4 cells had mutant p53. SW-1736 cells were functionally mutant because of marked down-regulation of wt p53 messenger ribonucleic acid, representing a novel mechanism of p53 dysfunction. Infection with a p53-expressing adenovirus (Ad-p53) induced high levels of p21 and Mdm-2 proteins. In BHT-101 cells, induction of p21 and Mdm-2 was evident 10 h after infection. In KAT-4 cells, induction of p21 and Mdm-2 was observed 1 day after infection, and continued to increase over the ensuing 24 h. SW-1736 cells demonstrated intermediate kinetics. Sensitivity to the cytotoxic effect of Ad-p53 paralleled the kinetics of p21/Mdm-2 induction. BHT-101 cells were most sensitive to killing by Ad-p53, with an IC,, of less than 2 multiplicity of infection; SW-1736 cells were intermediate in sensitivity; KAT-B cells were resistant. All three cell lines became more sensitive to adriamycin after wt p53 expression, with a 10-fold decrease in IC,, values. The latter observation may make a combination of wt p53 and chemotherapeutic drugs an attractive modality for treating anaplastic thyroid cancer.
引用
收藏
页码:2516 / 2522
页数:7
相关论文
共 23 条
[1]  
Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO
[2]  
2-6
[3]  
BLAGOSKLONNY MV, 1995, ONCOGENE, V57, P130
[4]   Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2 [J].
Blaydes, JP ;
Gire, V ;
Rowson, JM ;
WynfordThomas, D .
ONCOGENE, 1997, 14 (15) :1859-1868
[5]  
CLAYMAN GL, 1997, P AN M AM SOC CLIN, pA383
[6]   OVEREXPRESSION OF P53 AS A POSSIBLE PROGNOSTIC FACTOR IN HUMAN THYROID-CARCINOMA [J].
DOBASHI, Y ;
SAKAMOTO, A ;
SUGIMURA, H ;
MERNYEI, M ;
MORI, M ;
OYAMA, T ;
MACHINAMI, R .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (04) :375-381
[7]   GENE P53 MUTATIONS ARE RESTRICTED TO POORLY DIFFERENTIATED AND UNDIFFERENTIATED CARCINOMAS OF THE THYROID-GLAND [J].
DONGHI, R ;
LONGONI, A ;
PILOTTI, S ;
MICHIELI, P ;
DELLAPORTA, G ;
PIEROTTI, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1753-1760
[8]  
Fagin JA, 1996, CANCER RES, V56, P765
[9]   HIGH PREVALENCE OF MUTATIONS OF THE P53 GENE IN POORLY DIFFERENTIATED HUMAN THYROID CARCINOMAS [J].
FAGIN, JA ;
MATSUO, K ;
KARMAKAR, A ;
CHEN, DL ;
TANG, SH ;
KOEFFLER, HP .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :179-184
[10]   Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization [J].
Giannakakou, P ;
Sackett, DL ;
Kang, YK ;
Zhan, ZR ;
Buters, JTM ;
Fojo, T ;
Poruchynsky, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (27) :17118-17125